Clinical trial

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple…

NCT00240617 · GlaxoSmithKline, Industry · Completed

Key facts

NCT number NCT00240617
Title Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks
Official title A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima* (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks (*Treximet)
Lead sponsor GlaxoSmithKline, Industry
Status Completed
Phase Phase 3
Study type Interventional
Conditions Migraine Disorders
Intervention type Drug
Interventions sumatriptan succinate/naproxen sodium, placebo
Enrollment 623
Start date Oct 1, 2005
Primary completion Jun 1, 2006
Completion Jun 1, 2006
First posted Oct 18, 2005
Last update posted Oct 26, 2016
Countries United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies